Guofen Yang

425 total citations
26 papers, 317 citations indexed

About

Guofen Yang is a scholar working on Molecular Biology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, Guofen Yang has authored 26 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Reproductive Medicine and 9 papers in Cancer Research. Recurrent topics in Guofen Yang's work include Ovarian cancer diagnosis and treatment (9 papers), RNA modifications and cancer (5 papers) and Clusterin in disease pathology (5 papers). Guofen Yang is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), RNA modifications and cancer (5 papers) and Clusterin in disease pathology (5 papers). Guofen Yang collaborates with scholars based in China, United States and Sweden. Guofen Yang's co-authors include Dan Xie, Canquan Zhou, Yubin Li, Qiong Wang, Zeshan You, Yingrong Lai, Yanxia Fu, Hui‐Ling Lai, Muyan Cai and Haihong Zhang and has published in prestigious journals such as Chemical Communications, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Guofen Yang

25 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guofen Yang China 10 154 92 87 73 72 26 317
Herta Bettendorf Germany 12 217 1.4× 65 0.7× 92 1.1× 68 0.9× 41 0.6× 15 387
Gonghua Qi China 10 157 1.0× 91 1.0× 102 1.2× 73 1.0× 21 0.3× 16 365
Ouping Huang China 11 154 1.0× 113 1.2× 34 0.4× 72 1.0× 24 0.3× 26 317
Iason Psilopatis Germany 12 125 0.8× 70 0.8× 51 0.6× 53 0.7× 22 0.3× 42 279
Klaudia Klicka Poland 9 165 1.1× 74 0.8× 27 0.3× 136 1.9× 61 0.8× 11 324
Jianli Zhao China 6 100 0.6× 33 0.4× 110 1.3× 66 0.9× 54 0.8× 19 252
Yapei Zhu China 11 123 0.8× 57 0.6× 63 0.7× 79 1.1× 15 0.2× 15 284
Brian Orr United States 9 129 0.8× 134 1.5× 114 1.3× 91 1.2× 10 0.1× 27 411
Marcin Jędryka Poland 11 59 0.4× 167 1.8× 71 0.8× 61 0.8× 23 0.3× 34 303

Countries citing papers authored by Guofen Yang

Since Specialization
Citations

This map shows the geographic impact of Guofen Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guofen Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guofen Yang more than expected).

Fields of papers citing papers by Guofen Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guofen Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guofen Yang. The network helps show where Guofen Yang may publish in the future.

Co-authorship network of co-authors of Guofen Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Guofen Yang. A scholar is included among the top collaborators of Guofen Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guofen Yang. Guofen Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wen, Weijia, Hongye Jiang, Guofen Yang, et al.. (2025). Establishment and validation of a prognostic model based on vasculogenic mimicry-related gene clustering in ovarian cancer. Frontiers in Oncology. 15. 1575694–1575694.
2.
Zhang, Chunyu, Jiaying Li, Weijia Wen, et al.. (2024). CircMAST1 inhibits cervical cancer progression by hindering the N4-acetylcytidine modification of YAP mRNA. Cellular & Molecular Biology Letters. 29(1). 25–25. 8 indexed citations
3.
Lai, Hui‐Ling, Yunyun Guo, Qiyu Zhong, et al.. (2023). Necroptosis‐related regulatory pattern and scoring system for predicting therapeutic efficacy and prognosis in ovarian cancer. Cancer Reports. 6(10). e1893–e1893. 2 indexed citations
4.
Li, Xuemei, Hui‐Ling Lai, Tingting Sun, et al.. (2023). SLC11A2: a promising biomarker and therapeutic target in ovarian cancer. Scientific Reports. 13(1). 1132–1132. 5 indexed citations
5.
Xia, Canwei, et al.. (2023). The adaptive evolution of cancer driver genes. BMC Genomics. 24(1). 215–215. 2 indexed citations
6.
Chen, Yuying, et al.. (2022). A novel necroptosis-related lncRNA signature for predicting prognosis and anti-cancer treatment response in endometrial cancer. Frontiers in Immunology. 13. 1018544–1018544. 14 indexed citations
7.
Yang, Guiping, et al.. (2022). Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer. Journal of Ovarian Research. 15(1). 55–55. 2 indexed citations
8.
Sun, Tingting, Yu Zheng, Xiaohui Li, et al.. (2022). Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity. Journal of Advanced Research. 48. 213–225. 3 indexed citations
9.
Lai, Hui‐Ling, Tingting Sun, Yuanyuan Li, et al.. (2020). Non-target genetic manipulation induces rhabdomyosarcoma in KrasPten-driven mouse model of ovarian cancer. Translational Cancer Research. 9(12). 7458–7468. 2 indexed citations
10.
Yang, Guiping, Hui‐Ling Lai, Yu Zheng, et al.. (2020). CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2. International Journal of Medical Sciences. 17(15). 2387–2395. 9 indexed citations
11.
Li, Xiaohui, Zuwei Zhang, Hongwei Shen, et al.. (2020). A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses. Gynecologic Oncology. 160(3). 704–712. 15 indexed citations
12.
Shen, Hongwei, et al.. (2018). Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer. The Tohoku Journal of Experimental Medicine. 245(3). 141–148. 7 indexed citations
13.
Zhou, Juan, Wen‐Wen Zhang, San‐Gang Wu, et al.. (2017). The prognostic value of histologic subtype in node-positive early-stage cervical cancer after hysterectomy and adjuvant radiotherapy. International Journal of Surgery. 44. 1–6. 15 indexed citations
14.
Li, Xiaoqing, Wenhui Hou, Linjing Yuan, et al.. (2016). Overexpression of RNF2 is positively associated with ovarian carcinoma aggressiveness and indicative of poor patient survival. Oncotarget. 0(0). 9 indexed citations
15.
Fu, Yanxia, et al.. (2015). Lentivirus-mediated shRNA interference of clusterin blocks proliferation, motility, invasion and cell cycle in the ovarian cancer cells. Journal of Ovarian Research. 8(1). 59–59. 14 indexed citations
16.
Fu, Yanxia, Yingrong Lai, Xingyang Liu, et al.. (2013). Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer. Molecular Medicine Reports. 7(6). 1726–1732. 26 indexed citations
17.
Yang, Guofen, Haihong Zhang, Yu Liu, et al.. (2012). Epigenetic and immunohistochemical characterization of the Clusterin gene in ovarian tumors. Archives of Gynecology and Obstetrics. 287(5). 989–995. 9 indexed citations
18.
Yang, Guofen, Muyan Cai, Fei Luo, et al.. (2011). Loss/Down-Regulation of Tumor Suppressor in Lung Cancer 1 Expression Is Associated With Tumor Progression and Is a Biomarker of Poor Prognosis in Ovarian Carcinoma. International Journal of Gynecological Cancer. 21(3). 486–493. 25 indexed citations
19.
Yang, Guofen, et al.. (2009). Overexpression of Clusterin in Ovarian Cancer is Correlated With Impaired Survival. International Journal of Gynecological Cancer. 19(8). 1342–1346. 37 indexed citations
20.
Yang, Guofen, Xiaoming Li, & Dan Xie. (2007). Clusterin protein expression and apoptosis in ovarian cancer. Clinical Oncology and Cancer Research. 34(12). 14–16. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Herta Bettendorf Breakdown of academic impact, for papers by Gonghua Qi Breakdown of academic impact, for papers by Ouping Huang Breakdown of academic impact, for papers by Iason Psilopatis Breakdown of academic impact, for papers by Klaudia Klicka Breakdown of academic impact, for papers by Jianli Zhao Breakdown of academic impact, for papers by Yapei Zhu Breakdown of academic impact, for papers by Brian Orr Breakdown of academic impact, for papers by Marcin Jędryka
Rankless by CCL
2026